SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery left internal mammary artery (LIMA) take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.
The company celebrated the milestone in a LinkedIn post, stating, “We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region.” The post continued, “At SS Innovations International, Inc. we remain committed to enabling hospitals and…” For more details, see the Read More link. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
This expansion underscores the growing adoption of robotic-assisted surgery in cardiac care, a field where precision and minimally invasive techniques are critical. The SSi Mantra system’s use for a LIMA take-down—a key step in coronary artery bypass grafting—demonstrates its capability in complex cardiac procedures. For patients in India, this means access to advanced surgical options that may lead to smaller incisions, reduced pain, and faster recovery times compared to traditional open-heart surgery.
SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka, and the Philippines. This global growth signals increasing trust in the technology and positions SS Innovations as a key player in the competitive surgical robotics market. The company is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets. Achieving these regulatory milestones could open doors to the largest healthcare markets, potentially accelerating revenue growth and further validating the system’s safety and efficacy.
For the healthcare industry, this announcement highlights the accelerating trend of robotic-assisted surgery moving beyond general procedures into specialized fields like cardiac surgery. Hospitals investing in such systems may gain a competitive edge by offering cutting-edge treatments. However, the adoption of robotic systems also requires significant training and investment, which could strain resources for some institutions. As SS Innovations continues its global expansion, stakeholders should watch for updates on regulatory approvals and clinical outcomes, which will be crucial for wider acceptance.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer. View the original release on www.newmediawire.com.
